Therapeutic drug monitoring countering the effect of anti-infliximab antibodies

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Access to Document

@article{0064a36d624243eb8999c764221dd037,

title = "Therapeutic drug monitoring countering the effect of anti-infliximab antibodies",

author = "Femke Hooijberg and Gertjan Wolbink",

year = "2024",

month = apr,

day = "1",

doi = "10.1016/S2665-9913(24)00040-7",

language = "English",

volume = "6",

pages = "e193--e194",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Therapeutic drug monitoring countering the effect of anti-infliximab antibodies

AU - Hooijberg, Femke

AU - Wolbink, Gertjan

PY - 2024/4/1

Y1 - 2024/4/1

UR - http://www.scopus.com/inward/record.url?scp=85187563795&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(24)00040-7

DO - 10.1016/S2665-9913(24)00040-7

M3 - Comment/Letter to the editor

C2 - 38402892

SN - 2665-9913

VL - 6

SP - e193-e194

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 4

ER -